Bispecific antibodies (BsAbs) have demonstrated efficacy in newly diagnosed and
relapsed/refractory (R/R) lymphomas. BsAbs form immune synapses between effector cells …

The current standard of care in smoldering multiple myeloma (SMM) is close surveillance,
outside of clinical trials. Efforts are being made to understand the pathobiologic process that …

Background Patients with relapsed/refractory multiple myeloma are at increased risk of
infection. Infections during treatment with teclistamab, the first B‐cell maturation antigen …

The COVID-19 pandemic has represented a major cause of morbidity/mortality worldwide,
overstressing health systems. Multiple myeloma (MM) patients show an increased risk for …

The present study is an overview of systematic reviews focusing on adverse events of
antimyeloma treatments. It provides a systematic description of adverse events as they are …

Chimeric antigen receptor-modified T cell (CAR T-cell) therapy has revolutionized the
management of hematological malignancies. In addition to impressive malignancy-related …

Infections are major cause of morbidity and mortality in patients with multiple myeloma.
Current treatment landscape of newly-diagnosed multiple myeloma includes different …

Lenalidomide-based regimens are effective treatment options for patients with
relapsed/refractory multiple myeloma (RRMM). However, they are associated with an …

Secondary antibody deficiency (SAD) is a subtype of secondary immunodeficiency
characterized by low serum antibody concentrations (hypogammaglobulinemia) or poor …

Abstract Sodium–glucose cotransporter 2 (SGLT-2) inhibitors are the only medications that
improve clinical outcomes regardless of baseline left ventricular ejection fraction. Despite …